澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NEUREN PHARMACEUTICALS LTD

22.530

+0.0800.36%

成交量：72.78萬

成交額：1,649.33萬

市值：28.53億

市盈率：96.82

高：23.220

開：23.200

低：22.180

收：22.450

52周最高：23.760

52周最低：11.000

股本：1.27億

流通股本：1.08億

量比：1.32

換手率：0.67%

股息：- -

股息率：- -

每股收益(TTM):0.233

每股收益(LYR):0.233

淨資產收益率：8.67%

總資產收益率：3.66%

市淨率：8.43

市盈率(LYR):96.82

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股+2.85%

資金流向

資金流入：

資金流出：

新聞資訊

強大的合作伙伴銷售業績推動Neuren Pharmaceuticals躍居澳大利亞行業基準榜首

若獲歐盟市場授權並上市，NEUREN PHARMACEUTICALS LTD 首筆商業銷售後將獲3500萬美元

Neuren Pharmaceuticals 正重新評估資本管理方案，包括延續股票回購與啓動税後股息

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/NEU.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":22.53,"timestamp":1787638320000,"preClose":22.45,"halted":0,"volume":727764,"delay":0,"changeRate":0.003563474387527922,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":0.2327,"marketStatus":"未開盤","change":0.08,"latestTime":"08-25 16:12:00 AEST","open":23.2,"high":23.22,"low":22.18,"amount":16493253,"amplitude":0.046325,"askPrice":22.58,"askSize":3404,"bidPrice":22.42,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.2327,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":22.45,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":1.318636,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NEU.AU","preClose":22.45,"auctionPrice":22.53,"auctionVolume":150050,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638203501}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"3.66%","roe":"8.67%","lyrEps":0.2327,"volumeRatio":1.318636,"shares":126639526,"dividePrice":0,"high":23.22,"amplitude":0.046325,"preClose":22.45,"low":22.18,"week52Low":11,"pbRate":"8.43","psRate":"44.13","week52High":23.76,"institutionHeld":0,"latestPrice":22.53,"committee":-0.545867,"eps":0.2327,"divideRate":0,"volume":727764,"delay":0,"ttmEps":0.2327,"open":23.2,"prevYearClose":18.61,"prevWeekClose":22.46,"prevMonthClose":18,"prevQuarterClose":17.75,"fiveDayClose":23.04,"twentyDayClose":17.05,"sixtyDayClose":14.21,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657946745","title":"強大的合作伙伴銷售業績推動Neuren Pharmaceuticals躍居澳大利亞行業基準榜首","url":"https://stock-news.laohu8.com/highlight/detail?id=2657946745","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657946745?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 11:34","pubTimestamp":1785900870,"startTime":"0","endTime":"0","summary":"BUZZ-强大的合作伙伴销售业绩推动Neuren Pharmaceuticals跃居澳大利亚行业基准榜首8月5日-**Neuren PharmaceuticalsNEU.AX股价一度上涨18.2%，至22.00澳元，创下自2025年10月31日以来的最高水平**** 该公司表示， (link) Acadia PharmaceuticalsACAD.O——NEU曾向其授予DAYBUE（特罗菲奈肽）口","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4T4420AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","LU2065171311.SGD","ACAD","LU2065169927.USD","BK4139","BK7096","LU2065171402.SGD","LU2065170008.USD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183210271","title":"若獲歐盟市場授權並上市，NEUREN PHARMACEUTICALS LTD 首筆商業銷售後將獲3500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183210271","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183210271?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 05:45","pubTimestamp":1782683146,"startTime":"0","endTime":"0","summary":"若其产品在欧盟获得市场授权并成功上市，NEUREN PHARMACEUTICALS LTD 将在完成首笔商业销售后，有权获得3500万美元的款项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118300837","title":"Neuren Pharmaceuticals 正重新評估資本管理方案，包括延續股票回購與啓動税後股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1118300837","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118300837?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 11:24","pubTimestamp":1779852294,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals 目前正在对其资本管理策略进行全面重估。公司考虑的方案包括继续执行现有的股票回购计划，以及启动派发税后股息。这一评估旨在优化资本结构，提升股东回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NEU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.0285}]}}